Nathalie Garçon

PharmD, PhD

CEO/CSO, BIOASTER

During, more than 24 years in the private sector, my career has led me to roles of increasing responsibility in the management of complex multi-disciplinary projects from discovery to life cycle management of vaccines, through staffs of scientists at international levels, from vaccine to drug delivery.

During that time, I have: designed, developed and implemented GSK’s adjuvants strategy leading to the licensure of the first new adjuvanted vaccine worldwide. Adjuvant technology is present today in up to 70% of GSK’s vaccines pipeline; Established and nurtured an extensive network of professionals within the academic, bio—tech, industries and governmental organizations in numerous countries covering four continents, to help develop and promote technologies in medicines.

This includes, Pasteur Institute, NIH, NIBIO (Japan) in particular; Built strong leadership capabilities in terms of people (up to 300 scientists across 2 continents and 4 sites), general strategy definition, milestones establishment, implementation and follow up; Had a leading role in supporting and driving global corporate objectives, communication of ideas and their implementation, and have put in place processes and committees to ensure smooth and flawless execution of technology integration into the pipeline.

Additionally, I was spokesperson for GSK vaccines for vaccines sciences and technologies.

 During the past 3 1/2 years, I have served as the CEO/CSO of BIOASTER, the IRT focusing on microbiology technology, one of the 8 technology institutes created by the French government in 2012. BIOASTER is a non for profit, private foundation, that drives collaborative projects between BIOASTER, academic and private partners in the fields of applied microbiology.